SpringWorks Therapeutics, Inc. (SWTX)

NASDAQ: SWTX · IEX Real-Time Price · USD
50.10
+0.90 (1.83%)
At close: Mar 27, 2024, 4:00 PM
50.50
+0.40 (0.80%)
After-hours: Mar 27, 2024, 6:24 PM EDT

Company Description

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer.

Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.

The company is also involved in the development of mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN); mirdametinib + lifirafenib, a combination therapy that is in Phase 1b clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat other genetically defined solid tumors, including Phase 1/2 clinical trial for the treatment of pediatric and young adult patients with low-grade gliomas.

In addition, it develops Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations.

The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib.

It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor.

The company was founded in 2017 and is headquartered in Stamford, Connecticut.

SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics logo
Country United States
Founded 2017
IPO Date Sep 13, 2019
Industry Biotechnology
Sector Healthcare
Employees 227
CEO Saqib Islam J.D.

Contact Details

Address:
1029 Corporation Way
Palo Alto, California 94303
United States
Phone (415) 962-9111
Website springworkstx.com

Stock Details

Ticker Symbol SWTX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0000813619
CUSIP Number 85205L107
ISIN Number US85205L1070
Employer ID 94-2551470
SIC Code 3081

Key Executives

Name Position
Saqib Islam J.D. Chief Executive Officer and Director
Francis I. Perier Jr., M.B.A. Chief Financial Officer
Dr. Badreddin Edris Ph.D. Chief Operating Officer
Bhavesh Ashar Chief Commercial Officer
Michael P. Nofi Chief Accounting Officer
Tai-An Lin Ph.D. Chief Scientific Officer
Kim Diamond Vice President of Communications and Investor Relations
Herschel S. Weinstein J.D. General Counsel and Secretary
Daniel J. Pichl Chief People Officer
Dr. James Cassidy M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Dec 9, 2011 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Dec 9, 2011 15-12B Securities registration termination
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Dec 6, 2011 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments